Allogene Therapeutics, Inc. - Common Stock (ALLO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ALLO on Nasdaq
Shares outstanding
228,416,724
Price per share
$1.72
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
162,467,989
Total reported value
$222,488,280
% of total 13F portfolios
0%
Share change
-22,343
Value change
+$74,117
Number of holders
167
Price from insider filings
$1.72
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Allogene Therapeutics, Inc. - Common Stock (ALLO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PFIZER INC 9% $30,183,895 22,032,040 Pfizer Inc. 06 Nov 2025
CITADEL ADVISORS LLC 6.1% $15,091,828 13,346,151 Kenneth Griffin 09 Jul 2025
Belldegrun Arie 5.8% +3.3% $18,149,993 +$794,362 13,248,170 +4.6% Arie Belldegrun, M.D. 31 Dec 2025
Chang David D 5.2% +6% $16,578,676 +$1,186,838 12,101,223 +7.7% David D. Chang, M.D., Ph.D. 31 Dec 2025
BlackRock, Inc. 5.3% $17,633,122 11,450,079 BlackRock, Inc. 31 Mar 2025
Lynx1 Capital Management LP 5.2% $16,747,073 10,874,723 Lynx1 Capital Management LP 31 Dec 2024
FMR LLC 4.9% -58% $15,747,811 -$20,861,062 10,225,851 -57% FMR LLC 28 Feb 2025

As of 31 Dec 2025, 167 institutional investors reported holding 162,467,989 shares of Allogene Therapeutics, Inc. - Common Stock (ALLO). This represents 71% of the company’s total 228,416,724 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Allogene Therapeutics, Inc. - Common Stock (ALLO) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pfizer Inc 9.6% 22,032,040 0% 13% $30,183,895
TPG GP A, LLC 8.2% 18,716,306 0% 0.95% $25,641,339
BlackRock, Inc. 7.7% 17,676,029 +0.92% 0% $24,216,160
CITADEL ADVISORS LLC 5.3% 12,111,420 -13% 0.01% $16,592,646
VANGUARD GROUP INC 4.1% 9,251,609 +2.6% 0% $12,674,704
PRIMECAP MANAGEMENT CO/CA/ 3.6% 8,139,840 +15% 0.01% $11,151,581
Patient Square Capital LP 2.2% 4,963,756 +66% 1.5% $6,800,346
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,932,910 +2.6% 0% $5,388,905
Frazier Life Sciences Management, L.P. 1.7% 3,868,750 0% 0.14% $5,300,188
Woodline Partners LP 1.5% 3,500,499 -20% 0.02% $4,795,684
TWO SIGMA INVESTMENTS, LP 1.5% 3,423,441 +1.2% 0.01% $4,690,114
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 3,209,275 -13% 0% $4,398,000
Wildcat Capital Management, LLC 1.3% 2,920,787 0% 2.9% $4,001,478
TWO SIGMA ADVISERS, LP 1.3% 2,890,200 +3.9% 0.01% $3,959,574
STATE STREET CORP 1.2% 2,761,400 +0.22% 0% $3,783,118
Kalehua Capital Management LLC 1.1% 2,546,129 0% 3.5% $3,488,197
Candriam S.C.A. 1% 2,305,644 0.02% $3,158,867
GOLDMAN SACHS GROUP INC 1% 2,289,458 +90% 0% $3,136,557
RENAISSANCE TECHNOLOGIES LLC 0.96% 2,187,084 -24% 0% $2,996,305
JANE STREET GROUP, LLC 0.95% 2,160,383 +78% 0% $2,959,725
Aberdeen Group plc 0.91% 2,086,332 +32% 0% $2,858,275
MILLENNIUM MANAGEMENT LLC 0.81% 1,841,307 -46% 0% $2,522,591
FMR LLC 0.63% 1,445,761 +103% 0% $1,980,692
AQR CAPITAL MANAGEMENT LLC 0.63% 1,429,247 -23% 0% $1,958,068
UBS Group AG 0.61% 1,389,593 -61% 0% $1,903,743

Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 162,467,989 $222,488,280 +$74,117 $1.37 167
2025 Q3 162,111,357 $201,031,283 -$24,340,170 $1.24 168
2025 Q2 183,617,614 $207,883,293 -$15,409,926 $1.13 153
2025 Q1 196,986,783 $288,577,139 +$11,150,657 $1.46 167
2024 Q4 188,657,885 $401,850,158 -$12,907,825 $2.13 170
2024 Q3 164,371,652 $460,365,265 -$1,917,859 $2.80 152
2024 Q2 165,184,059 $384,891,280 +$75,138,227 $2.33 169
2024 Q1 131,205,694 $586,006,096 +$44,997,765 $4.47 158
2023 Q4 122,248,338 $392,448,357 -$24,859,731 $3.21 167
2023 Q3 130,384,371 $413,319,837 -$17,479,237 $3.17 152
2023 Q2 133,404,417 $662,853,148 +$77,627,682 $4.97 168
2023 Q1 117,863,372 $582,311,658 +$28,545,426 $4.94 174
2022 Q4 111,615,016 $701,714,273 +$16,748,007 $6.29 166
2022 Q3 106,389,695 $1,148,387,442 +$56,535,530 $10.80 182
2022 Q2 100,792,050 $1,148,985,365 +$110,979,207 $11.40 155
2022 Q1 91,688,120 $835,872,818 +$16,130,116 $9.11 173
2021 Q4 85,813,394 $1,280,601,899 -$105,097,078 $14.92 168
2021 Q3 86,172,174 $2,214,699,254 +$36,168,155 $25.70 165
2021 Q2 86,340,537 $2,251,293,398 -$84,504,708 $26.08 175
2021 Q1 86,575,661 $3,055,834,294 -$11,800,278 $35.30 167
2020 Q4 87,569,716 $2,210,441,766 +$86,472,875 $25.24 160
2020 Q3 83,175,052 $3,136,521,357 -$164,131,449 $37.71 158
2020 Q2 86,937,058 $3,722,235,026 +$671,195,013 $42.82 170
2020 Q1 73,747,853 $1,390,700,983 +$46,546,025 $19.44 115
2019 Q4 71,621,156 $1,860,741,066 +$73,711,322 $25.98 114
2019 Q3 68,693,966 $1,760,955,637 +$43,711,782 $27.26 94
2019 Q2 68,882,259 $1,691,632,297 +$152,108,493 $26.85 94
2019 Q1 65,390,655 $1,661,573,471 +$80,500,361 $28.91 85
2018 Q4 54,998,315 $1,469,849,010 +$1,469,849,001 $26.93 78
2016 Q2 0 $0 -$115,000 $1.72 0
2016 Q1 4,033 $115,000 $28.51 1